#Sweden #Stockholm #Nevisense #SciBase #financial report

SciBase Holding AB Announces Delay in Year-End Report Publication

In a recent announcement, SciBase Holding AB (publ), a leading company in medical technology, has decided to postpone the release of its year-end financial report for the fiscal year 2025. Originally scheduled for an earlier date, the publication has been moved to March 13, 2026. This adjustment is primarily intended to synchronize the report's release with an ongoing rights issue, the subscription period of which is concluding on January 26, 2026.

The decision was made by the company's Board of Directors, who aim to ensure that shareholders and the market receive comprehensive and timely information that correlates with the company's financial strategies, particularly regarding the rights issue. Such moves indicate a growing commitment by SciBase to maintain transparency and provide clarity around its financial dealings.

Jesper Høiland, the Chairman of the Board, along with the Chief Financial Officer, Michael Colérus, are available for any inquiries. Høiland can be reached at +45 612 207 30, while Colérus can be contacted at +46 70 341 34 72. These contacts are crucial for investors seeking clarity concerning the implications of this new publication date and what changes in trading restrictions this may introduce.

About SciBase and Its Key Innovations

SciBase is renowned globally for its innovative contributions to dermatology and medical technology. It has developed a unique point-of-care platform named Nevisense, which integrates artificial intelligence (AI) with advanced Electrical Impedance Spectroscopy (EIS) technology. This powerful combination enhances the diagnostic accuracy crucial for proactive skin health management and early disease detection.

Founded on over two decades of research conducted at the prestigious Karolinska Institute in Stockholm, Sweden, SciBase functions with a clear mission: to reduce patient suffering through the timely identification and response to dermatological conditions. By leveraging cutting-edge technology, the company not only aims to improve clinical outcomes for patients but also to lower healthcare costs fundamentally.

SciBase has been listed on the Nasdaq First North Growth Market since June 2, 2015. The Certified Adviser for the company is DNB Carnegie Investment Bank AB (publ), which plays a vital role in assisting SciBase with compliance and advisory support, navigating the intricate landscape of public finance and shareholder communications.

Future Expectations

With the new date for the year-end report approaching, stakeholders are expected to closely monitor the developments surrounding the rights issue and how it aligns with company growth strategies. Investors will likely seek clarity regarding how these financial adjustments can support SciBase's innovation and market position.

As the medical field continues to evolve, particularly in the realm of technological advancements, SciBase remains at the forefront, committed to its mission of improving patient care and outcomes.

For further updates and more detailed reports, investors and interested parties are encouraged to visit SciBase’s official web page as well as their investor relations section. They can access comprehensive press releases and financial reports detailing the company’s performance, goals, and trajectory within the innovative field of dermatological technology and beyond.